What does a nivolumab (Opdivo) rash look like?
Nivolumab is an immune checkpoint inhibitor, and rashes can be part of its side effects. The exact appearance can vary, but patients commonly describe skin findings such as red patches, small bumps, itching, or a rash that spreads beyond the original area.
Because “rash pictures” can lead to misinterpretation, it’s safest to use images only as a reference and treat new or worsening skin symptoms as a medical issue—especially if they come with other symptoms (fever, blistering, mouth sores, eye redness, or feeling unwell).
How can you tell a concerning nivolumab rash from a mild one?
A rash is more concerning when it suggests a severe skin reaction. Seek urgent medical advice (or emergency care) if you notice any of the following:
- Blistering, peeling skin, or skin that looks “burned”
- Painful rash
- Sores in the mouth, eyes, or genitals
- Rapid spreading over hours to a day
- Fever, trouble breathing, or feeling severely ill
These can be signs of serious immune-related skin reactions that need prompt treatment.
What rash conditions are often mentioned with nivolumab?
Immune checkpoint inhibitors are associated with several types of skin reactions, and the look can overlap:
- Maculopapular rash (red patches with small raised bumps)
- Pruritic (itchy) dermatitis
- Vitiligo-like changes (loss of pigment in patches)
- More severe immune-mediated reactions that can include blistering/skin detachment in severe cases
A clinician usually confirms the type by exam (and sometimes a skin biopsy), because pictures alone can’t reliably distinguish mild drug rashes from serious immune reactions.
When should you contact your oncology team about a rash after nivolumab?
Contact your oncology team promptly if the rash:
- Starts soon after beginning nivolumab or after a dose change
- Is worsening over 24–48 hours
- Is spreading, becoming painful, or causing significant itch
- Persists despite basic measures (like moisturizers) or returns after it temporarily improves
If any blistering, peeling, or mucous membrane sores are present, treat it as urgent.
Are there official nivolumab rash photo resources?
If you want “rash pictures,” the most reliable approach is to look for rash management and immune-related adverse event resources from oncology/dermatology organizations or your treating center. Those sources typically categorize rashes by severity and include warnings for severe reactions.
If you share what you see (for example: red vs. purple, flat vs. raised, itchy vs. painful, any blisters/peeling, and whether you have mouth/eye symptoms), I can help you interpret what category it most resembles and what questions to ask your clinician.